Abstract:

Abstract:Objective To study the application of     ATP-tumor chemosensitivity assay of in vitro susceptibility test in the chemotherapy of  non-small cell lung cancer(NSCLC),and provide basis for selection of clinical therapy program.Methods 52 samples of NSCLC  with pleural fluid were selected and divided into two groups. The patients in experience treatment group(n=20)  were given the standard program based on experience ［Paclitaxel(PTX)+ Caboplatin(CBP)］;the  pleural fluid specimes in susceptibility treatment  group(n=32) were given in vitro susceptibility test for  cisplatin(DDP),navelbine(NVB),PTX,CBP,gemcitabine(GEM),PTX+CBP,navelbine and  NVB+CBP,GEM + DDP, the chemotherapy program was selected according to the results of in vitro susceptibility test;and the efficiency was compared between two groups. Results A single medication,NVB and PTX  had the highest efficiency of 28.1% to NSCLC in vitro,the efficiency of GEM was 25%,the efficiciency of CBP was 21.95%,the efficicency (17.6%)of DDP was the lowest.Combined program showed good therapeutic effect,in which GEM + DDP had the highest efficiency of 55.9% in vitro,and PTX + CBP  up to 50%.NVB+CBP had the lowest efficiency(40.6%) in vitro.The efficiency (65.6%) in suceptibihity treatment  group  was higher compared with  experience treatment group(40.0%)(P<0.05).Conclusion The efficiencies of different chemotherapy drugs for NSCLC in vitro are different.The chemotherapy program  based on susceptibility test can achieve better clinical efficacy than experience  chemotherapy program.

Key words: adenosine-triphosphate-tumor chemosensitivity assay;cancer,non-small cell lung;in　vitro susceptibility test;pleural fluid